1. Home
  2. UTHR vs RTO Comparison

UTHR vs RTO Comparison

Compare UTHR & RTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • RTO
  • Stock Information
  • Founded
  • UTHR 1996
  • RTO 1925
  • Country
  • UTHR United States
  • RTO United Kingdom
  • Employees
  • UTHR N/A
  • RTO N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • RTO Business Services
  • Sector
  • UTHR Health Care
  • RTO Consumer Discretionary
  • Exchange
  • UTHR Nasdaq
  • RTO Nasdaq
  • Market Cap
  • UTHR 14.4B
  • RTO 12.2B
  • IPO Year
  • UTHR 1999
  • RTO N/A
  • Fundamental
  • Price
  • UTHR $291.72
  • RTO $23.23
  • Analyst Decision
  • UTHR Buy
  • RTO Hold
  • Analyst Count
  • UTHR 13
  • RTO 1
  • Target Price
  • UTHR $393.08
  • RTO N/A
  • AVG Volume (30 Days)
  • UTHR 690.9K
  • RTO 545.4K
  • Earning Date
  • UTHR 07-30-2025
  • RTO 07-25-2025
  • Dividend Yield
  • UTHR N/A
  • RTO 2.52%
  • EPS Growth
  • UTHR 18.86
  • RTO N/A
  • EPS
  • UTHR 25.10
  • RTO 0.15
  • Revenue
  • UTHR $2,994,100,000.00
  • RTO $6,805,463,398.00
  • Revenue This Year
  • UTHR $14.30
  • RTO $15.25
  • Revenue Next Year
  • UTHR $6.32
  • RTO $4.21
  • P/E Ratio
  • UTHR $11.62
  • RTO $30.28
  • Revenue Growth
  • UTHR 19.84
  • RTO 1.14
  • 52 Week Low
  • UTHR $266.98
  • RTO $19.60
  • 52 Week High
  • UTHR $417.82
  • RTO $34.07
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 43.35
  • RTO 45.35
  • Support Level
  • UTHR $281.97
  • RTO $23.35
  • Resistance Level
  • UTHR $329.85
  • RTO $24.10
  • Average True Range (ATR)
  • UTHR 9.11
  • RTO 0.33
  • MACD
  • UTHR -3.44
  • RTO -0.09
  • Stochastic Oscillator
  • UTHR 29.04
  • RTO 2.40

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About RTO Rentokil Initial plc

Rentokil Initial is the largest global provider of route-based pest-control and commercial hygiene services, operating in 83 countries. The group also offers a range of specialist route-based services including office and commercial space plant care, property care, and workwear rentals. The group has a diverse client base that includes global food producers, hotel chains, industrial goods businesses, restaurants, and individual residential customers.

Share on Social Networks: